Clinical Trial Detail

NCT ID NCT03436862
Title Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors SCRI Development Innovations, LLC
Indications

Hodgkin's lymphoma

Therapies

Nivolumab

Age Groups: adult senior

No variant requirements are available.